Becton, Dickinson and Company $BDX Shares Sold by E. Ohman J or Asset Management AB

Key Points

• E. Ohman J or Asset Management AB drastically reduced its stake in Becton, Dickinson and Company by 93.0%, selling 162,097 shares, and now holds just 12,200 shares valued at approximately $2.1 million.
• Insider transactions included EVP Michael David Garrison selling 1,185 shares and Director Claire Fraser selling 917 shares, indicating decreased ownership stakes for both executives.
• The company reported a quarterly earnings per share of $3.68, exceeding analysts' expectations, and has set a fiscal year 2025 guidance of 14.300-14.450 EPS.

E. Ohman J or Asset Management AB lessened its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 93.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,200 shares of the medical instruments supplier's stock after selling 162,097 shares during the quarter. E. Ohman J or Asset Management AB's holdings in Becton, Dickinson and Company were worth $2,101,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Brighton Jones LLC boosted its holdings in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after buying an additional 877 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in shares of Becton, Dickinson and Company by 50.6% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock valued at $18,808,000 after purchasing an additional 27,581 shares during the period. FORA Capital LLC acquired a new stake in Becton, Dickinson and Company in the 1st quarter valued at about $3,458,000. Foster Victor Wealth Advisors LLC acquired a new stake in Becton, Dickinson and Company during the first quarter valued at approximately $6,406,000. Finally, GAMMA Investing LLC boosted its stake in shares of Becton, Dickinson and Company by 29.9% during the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock worth $744,000 after acquiring an additional 748 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Claire Fraser sold 917 shares of the company's stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 2,965 shares of company stock worth $551,536 over the last quarter. Company insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Trading Down 0.5%

BDX opened at $185.90 on Tuesday. The firm has a market capitalization of $53.29 billion, a price-to-earnings ratio of 33.44, a PEG ratio of 1.51 and a beta of 0.27. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The company's 50 day moving average price is $186.72 and its two-hundred day moving average price is $190.98.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.28. The company had revenue of $5.51 billion during the quarter, compared to analysts' expectations of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Becton, Dickinson and Company's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the prior year, the company posted $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 74.82%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Morgan Stanley boosted their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Citigroup lowered shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and dropped their price target for the stock from $217.00 to $185.00 in a research note on Thursday, May 22nd. Wells Fargo & Company boosted their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a report on Friday, August 8th. Piper Sandler reaffirmed a "neutral" rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Finally, Barclays reduced their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a report on Tuesday, June 3rd. Four equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $211.44.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.